Dysregulation of humoral immunity following Plasmodium infection
NIAID - National Institute of Allergy and Infectious Diseases
About This Grant
ABSTRACT Immune-mediated protection against malaria, termed clinical immunity, develops over many years of repeated exposure to Plasmodium, requires continuous exposure to Plasmodium, and correlates with circulating titers of Plasmodium-specific antibodies. Why Plasmodium infections fail to induce long-lasting protection following one or few infections, thereby contributing to the chronic pathogenesis of malaria, remains unknown. The objective of this proposal is to determine the effect of Plasmodium infections on germinal center (GC) B cells and bone marrow (BM) homeostasis towards inefficient generation of long-lived plasma cells (LLPCs). Many infections and vaccines elicit long-lasting antibody titers after one or just a few exposures. The half-lives of circulating antibody titers for viral antigens following infection or vaccination have been shown to range from 10 years to >300 years. In contrast, half-lives of circulating Plasmodium-specific antibody titers are reported to be in the range of several days. Long-term maintenance of circulating antibody titers comes from GC-derived plasma cells (PCs) that migrate to the BM where they receive survival signals and become LLPCs. To investigate why Plasmodium infection induces short antibody half-lives, we compared spleen GC responses and development of BM LLPCs in mice following infection with Plasmodium yoelii 17XNL (Py) to mice immunized systemically with NP-CGG plus the adjuvant AddaVax. Our preliminary data demonstrate that despite the induction of robust spleen GC responses during Py infection, Py-induced GC B cells are inefficient at generating LLPCs in the spleen and BM and that Py-specific IgG-secreting cells in the spleen and BM exhibit decreased IgG production and affinity. These data suggest Py infections exhibit dysregulated humoral immunity by impacting the functional programming of spleen GC B cells or PCs. Py-induced splenic PCs were able to migrate towards the BM homing cytokine CXCL12, suggesting inefficient generation of LLPCs following Py infection could be attributed to functional deficiencies in the BM microenvironment that support engraftment and survival of LLPCs. Consistent with this possibility, there were decreases in the number of BM cells that provide recruitment signals for PCs and survival signals for LLPCs during Py infection that was associated with an increase in multiple cytokines in the BM, including IFN-γ. Blocking IFN-γR signaling during Py infection partially prevented the loss of BM cells and increased BM PC numbers. These observations collectively lead to the hypothesis that failure to engender LLPCs following Plasmodium infection is attributed to intrinsic differences in spleen GC B cell programming that affect PC functionality and changes in the BM microenvironment that fail to support LLPCs. The hypothesis will be tested through the following aims. Aim 1. Identify the functional deficits in spleen GC B cells and PCs following Py infection responsible for inefficient generation and function of LLPCs. Aim 2. Define the cellular and molecular mechanisms by which Py alters the BM microenvironment to impede the development of LLPCs.
Grant Summary
Dysregulation of humoral immunity following Plasmodium infection is a NIAID - National Institute of Allergy and Infectious Diseases grant providing up to $791K for university, nonprofit, healthcare org. Applications are due 2031-01-31 (open). Check eligibility and apply with FindGrants.
Not quite the right fit?
Search 9,000+ open grants, or get matches ranked for your organization — free.
Focus Areas
Eligibility
How to Apply
Up to $791K
2031-01-31
- 1Confirm your organization is eligible for Dysregulation of humoral immunity following Plasmodium infection from NIAID - National Institute of Allergy and Infectious Diseases, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NIAID - National Institute of Allergy and Infectious Diseases before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NIAID - National Institute of Allergy and Infectious Diseases's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Dysregulation of humoral immunity following Plasmodium infection: Frequently Asked Questions
Who is eligible for the Dysregulation of humoral immunity following Plasmodium infection?
Dysregulation of humoral immunity following Plasmodium infection is offered by NIAID - National Institute of Allergy and Infectious Diseases and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Dysregulation of humoral immunity following Plasmodium infection provide?
Dysregulation of humoral immunity following Plasmodium infection provides up to $791K per award from NIAID - National Institute of Allergy and Infectious Diseases. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Dysregulation of humoral immunity following Plasmodium infection deadline?
Applications for Dysregulation of humoral immunity following Plasmodium infection are due 2031-01-31 (open). Because deadlines can change, verify the date with the funder, NIAID - National Institute of Allergy and Infectious Diseases, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the Dysregulation of humoral immunity following Plasmodium infection?
To apply for Dysregulation of humoral immunity following Plasmodium infection, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NIAID - National Institute of Allergy and Infectious Diseases.